https://www.selleckchem.com/pr....oducts/Nicotinamide(
Furthermore, a new prediction model was developed that consisted of four predictors F8 gene mutation, intensity of first treatment with FVIII, the presence of factor VIII non-neutralizing antibodies before treatment initiation and lastly FVIII product type (recombinant vs. plasma-derived). The C-statistic was 0.66 (95 CI 0.57-0.75), and calibration was moderate. Using a model cut-off point of 10%, positive- and negative predictive values were 0.22 and 0.95, respectively. Performance of all prediction models was limited
Like
Comment
Share
